Is hexarelin approved for human use?

No. It has been used in human research studies but is not approved as a medicine; it is research-use-only.

What are hexarelin's cardiovascular effects?

Rodent studies show improved cardiac function after heart attack and reduced cardiac fibrosis, effects thought to involve the CD36 receptor. These findings are preclinical and not established in humans.

Does hexarelin keep working with repeated use?

The GH response can diminish with repeated administration, a desensitization pattern noted in human studies.

Only acute, supervised human dosing has been studied. Long-term and self-directed safety are not established, and this content is informational, not medical advice.

Research chemical — not approvedaka Examorelin

Hexarelin — Complete Research Guide (2026)

Last updated 2026-06-25

TL;DR

A potent synthetic growth-hormone-releasing hexapeptide studied for GH release and cardiovascular effects in early research.

What is Hexarelin?

Hexarelin is a synthetic GH-releasing hexapeptide and ghrelin-receptor (GHS-R1a) agonist that potently stimulates pituitary growth-hormone secretion.

It has been studied in both humans (GH-stimulation and endocrine-diagnostic work) and animals (cardiovascular models), but it is not an approved drug and remains research-use-only.

Evidence level is moderate for GH-releasing activity in humans and preclinical for its cardiovascular effects.

How does Hexarelin work?

Hexarelin activates the growth-hormone secretagogue receptor (GHS-R1a) on the pituitary and hypothalamus to trigger GH release, acting independently of the GHRH receptor.

It also binds CD36 in cardiovascular tissue, a receptor interaction implicated in its GH-independent cardiac effects observed in animal studies. [INFOGRAPHIC: Hexarelin GHS-R1a and CD36 pathways]

What does the research say about Hexarelin?

Hexarelin produces a dose-dependent rise in growth hormone in healthy adults, making it one of the more potent GH-releasing hexapeptides characterized in humans. ^[1]
The magnitude of the GH response to hexarelin differs by the site of hypothalamic-pituitary damage, giving the peptide diagnostic value for localizing causes of GH deficiency. ^[2]
In rodent models, hexarelin improved cardiac function after experimental myocardial infarction, a GH-independent cardiovascular effect under preclinical investigation. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Growth hormone-releasing activity of hexarelin in humans. A dose-response study — Imbimbo BP et al., Eur J Clin Pharmacol 1994. (human dose-response)
[2] The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities — Maghnie M et al., J Clin Endocrinol Metab 1998. (human clinical)
[3] Metabolic modulation of the growth hormone-releasing activity of hexarelin in man — Maccario M et al., Metabolism 1995. (human study)
[4] The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction — Tivesten A et al., Endocrinology 2000. (animal (rat))
[5] Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat — Xu X et al., Am J Physiol Heart Circ Physiol 2007. (animal (rat))
[6] Hexarelin induced growth hormone release is influenced by exogenous growth hormone — Massoud AF et al., Clin Endocrinol (Oxf) 1995. (human study)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In the research literature hexarelin is given as weight-based intravenous or subcutaneous boluses purely to measure GH responses or to model cardiovascular effects.

Any reported amounts reflect controlled experimental protocols and are not treatment recommendations for individuals.

Side effects & safety profile

Human studies used acute or short-course administration under clinical supervision and generally reported good tolerability of single provocative doses.

Repeated dosing can attenuate the GH response over time, and long-term human safety of therapeutic or self-directed use is not established.

No reliable human half-life is asserted here; pharmacokinetic details are inconsistently reported and route-dependent.

Stacking & combinations

In research settings hexarelin has been co-administered with GHRH to amplify the GH-stimulation response for diagnostic evaluation.

Finding Hexarelin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

A synthetic GH-releasing hexapeptide and ghrelin-receptor agonist studied for its potent growth-hormone-stimulating and, in animals, cardiovascular effects. It is not an approved drug.

References

[1] Growth hormone-releasing activity of hexarelin in humans. A dose-response study — Imbimbo BP et al., Eur J Clin Pharmacol 1994. PMID: 7957536. View sourceStudy: human dose-responseHexarelin dose-dependently stimulated GH release in healthy human volunteers.
[2] The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities — Maghnie M et al., J Clin Endocrinol Metab 1998. PMID: 9814463. View sourceStudy: human clinicalThe GH response to hexarelin varied by the site of hypothalamic-pituitary abnormality, aiding lesion localization.
[3] Metabolic modulation of the growth hormone-releasing activity of hexarelin in man — Maccario M et al., Metabolism 1995. PMID: 7854159. View sourceStudy: human studyMetabolic state modulated the magnitude of hexarelin-induced GH release in humans.
[4] The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction — Tivesten A et al., Endocrinology 2000. PMID: 10614623. View sourceStudy: animal (rat)Hexarelin improved cardiac function in rats after experimental myocardial infarction.
[5] Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat — Xu X et al., Am J Physiol Heart Circ Physiol 2007. PMID: 17766487. View sourceStudy: animal (rat)Hexarelin reduced cardiac fibroblast proliferation and collagen synthesis in rat tissue.
[6] Hexarelin induced growth hormone release is influenced by exogenous growth hormone — Massoud AF et al., Clin Endocrinol (Oxf) 1995. PMID: 8548947. View sourceStudy: human studyExogenous GH feedback modulated hexarelin-induced GH release in humans.

Related peptides

GHRP-2Growth Hormone GHRP-6Growth Hormone IpamorelinGrowth Hormone

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.